Cancer pharmacology Flashcards

1
Q

Bone marrow suppression

A

Also called “myelosuppression”, used interchangeably
Highly toxic to bone marrow because cells of this tissue are rapidly proliferating and in an active state
Reduces circulating neutrophils, erythrocytes, and platelets
High risk for infection (low neutrophils), bleeding (low platelets), and anemia (low erythrocytes)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Neutropenia count

A

Normal neutrophil count = 2500-7000 cells/mm3
Neutropenia = absolute neutrophil count (ANC) < 500/mm3

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Neutropenia

A

Neutrophils → WBCs that fight infection
Incidence and severity of infection increase with a decrease in circulating neutrophils
Most cytotoxic drugs will cause a rapid onset of neutropenia with rapid recovery
Begins to develop 2-3 days after dosing
Lowest neutrophil count (called the Nadir) occurs between day 10 and day 14
Patients are highest risk during the Nadir

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Neutropenia precautions

A

Neutrophil counts must be monitored carefully → chemotherapy should be held until neutrophil counts improve
High risk of developing infection from normal flora of the body
*** low neutrophils hide signs of infection → usual signs of infection such as pus, abscesses, and infiltrates may not be present
Fever is the main sign of infection in someone with low neutrophils

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Neutropenia nursing considerations

A

EDUCATION →
-the risks of developing neutropenia and their risk for infection
-minimize contact with others
-avoid crowds
-report a fever immediately to the health care provider
-Hand washing
-Regular cleansing of skin and oral cavity
When hospitalized, placed in isolation
Frequently monitored for fever
Foods that have high risk to carry pathogens should be avoided (meat, vegetables, fruit)
Pan culture patient (Blood cultures, urine cultures, wound cultures, sputum cultures) as soon as patient shows signs of infection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Thrombocytopenia

A

Reduced circulating platelets
Increased risk in bleeding
Common signs → bleeding gums and nose bleeds
Normal platelet count = 150,000-300,000 cells/mm3
Thrombocytopenia = Platelet count < 150,000/mm3

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Thrombocytopenia nursing considerations

A

Patients should not take medications that induce bleeding (for example, aspirin, anticoagulants, etc)
Patients should avoid vigorous tooth brushing and must be careful when shaving
Procedures such as IV insertions should be done very carefully. Subcutaneous and intramuscular injections should be avoided
Nurses must be cautious when applying blood pressure cuff, as overinflation may cause bruising

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Anemia

A

Reduction in circulating erythrocytes
Anemia is less common than thrombocytopenia and neutropenia→ erythrocytes have a longer life span (120 days) allowing for recovery before levels fall too low
Monitor for signs of anemia, fatigue, pallor, shortness of breath

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Digestive Tract Dysfunction: Stomatitis

A

Inflammation of the oral mucosa
Develops 2-3 days after start of chemotherapy
May continue up until > 2 weeks after treatment has stopped
Begins as inflammation and can progress to ulceration
Can lead to infection
Causes pain which affects eating, speaking, and swallowing
Assess oral mucosa regularly
Weigh patient and monitor intake

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Digestive Tract Dysfunction: Diarrhea

A

Destruction of epithelial lining of the intestine affects absorption of nutrients and fluids, causing diarrhea
This impairs nutrition, hydration, and may lead to infection due to impaired skin integrity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Alopecia

A

Also known as “hair loss”
Results from injury to hair follicles, which rapidly proliferate
Occurs with most cytotoxic medications
Begins 7-10 days after start of treatment and peaks at 1-2 months
Hair will grow back 1-2 months after treatment ends
Not life threatening, however very common fear in cancer patients
Patients should be warned of the potential for hair loss
Wigs and hair pieces should be chosen prior to the hair loss occurring

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Reproductive Toxicity

A

Cytotoxic medications interfere with early embryo development
May cause fetal malformation and death → more common in first trimester
Research shows after 18 weeks, risk is very low to the fetus
Chemotherapy can cause irreversible sterility in men
Men should be provided with education on sperm banking
Cytotoxic meds can also affect the ovaries leading to amenorrhea and menopausal symptoms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Extravasation

A

is the leakage of drug from the blood vessel into the surrounding tissues
Extravasation can cause pain, infection, loss of mobility, and in severe cases necrosis and sloughing
If the patient shows signs of extravasation (redness, swelling, blisters at the site), the infusion should be stopped immediately

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Carcinogenesis

A

Cytotoxic drugs can cause cancer
By damaging DNA, chemo drugs can promote cancer to develop
This may occur years after treatment
More likely to occur with Alkylating Agents

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Cyclophosphamide

A

Cause alkylation of DNA which destroys the DNA in cancer cells
Prevent cells from being able to repair themselves
Cell-cycle phase non-specific → can act during any phase of the cell cycle
More toxic to rapidly dividing cells compared to cells in the inactive G0 state because alkylation of DNA is more lethal when cells are actively trying to replicate DNA
Cyclophosphamide is the most common Alkylating Agent
Non vesicant → can therefore be administered orally and intravenously
Commonly causes bone marrow suppression, nausea/vomiting, alopecia, and can also cause acute bladder injury and hemorrhagic cystitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Methotrexate

A

Activated Folic Acid is required for DNA and RNA synthesis
Tetrahydrofolic acid (FH4) is necessary to activate the folic acid
Methotrexate blocks the conversion of folic acid to its activated form, thereby disrupting DNA synthesis
S-Phase specific
Common toxicities include: Bone marrow suppression, pulmonary fibrosis, oral and GI ulceration, and nausea/vomiting

17
Q

Leucovorin Rescue

A

Technique used to enhance effects of methotrexate while reducing harm to normal cells
Leucovorin (Calcium Folinate)
Reduced form of folic acid that bypasses the metabolic “block” caused by methotrexate
Can be used 24 hours after methotrexate administration to “rescue” normal cells from adverse reactions
This drug will not save malignant cells
Is also used with fluorouracil to enhance cytotoxic effects

18
Q

Fluorouracil

A

Inhibit synthesis of DNA and RNA
Treats solid tumors
Inhibits thymidylate synthetase which is required by cells to make DNA
S-Phase Specific
Administered IV
Commonly causes bone marrow suppression, and oral and GI ulceration.

19
Q

Doxorubicin (Anthracycline Derivative)

A

Isolated from cultures of Streptomyces
Injure cells through direct interaction with DNA
Slips in between base pairs of DNA and binds to the DNA → by doing so, it distorts the DNA structure and inhibits DNA synthesis
Only used to treat cancer (both solid and disseminated cancer)
Always administered parenterally (usually via IV)
Can cause severe bone marrow suppression and heart damage
Cardiotoxicity can lead to fatal heart failure
Cardiac effects can be acute or delayed  acute includes arrythmias (only last for approximately 2 weeks) or delayed effects include heart failure secondary to cardiomyopathy (develop months to years after treatment)

20
Q

Bleomycin (Non-Anthracycline Derivative)

A

Isolated from cultures of Streptomyces
Injure cells through direct interaction with DNA
Slips in between base pairs of DNA and binds to the DNA → by doing so, it distorts the DNA structure and inhibits DNA synthesis
Most effective during G2 phase
Administered parenterally (IV, Subcut, IM)
Causes very little bone marrow suppression
Causes severe injury to lungs (10% of patients)
Lung injury manifests as pneumonitis which can progress to fibrosis and death
Other toxicities include, stomatitis, alopecia, and skin reactions

21
Q

Vincristine

A

Act during M phase to prevent cell division
Vinca Alkaloids derive from the periwinkle plant Madagascar Periwinkle
Blocks mitosis during metaphase by disrupting the organization of microtubules (which normally move chromosomes during cell division)
Without microtubules, cell division will stop
Must be administered IV (it is a vesicant)
Toxic to peripheral nerves causing peripheral neuropathy → almost all patients will experience sensory and or motor nerve injury
Symptoms include paresthesia, weakness, sensory loss, decreased reflexes
Minimally affects bone marrow

22
Q

Paclitaxel

A

Acts during late G2 phase and M phase, inhibiting cell division
Administered via IV
Toxicities include severe hypersensitivity reactions  hypotension, dyspnea, angioedema, and hives (urticaria)
Bone marrow suppression, alopecia, peripheral neuropathy, cardiotoxicity (bradycardia, heart blocks, myocardial infarction) can also occur

23
Q

Chemo Nursing Considerations

A

All chemo medications are considered high alert medications → in the event of a medication error, can pose significant risk to the patient
Most chemo drugs are carcinogenic, teratogenic, and mutagenic → can pose severe risk if handled incorrectly
Direct contact with eyes, mucous membranes, and skin can cause local injury
FOLLOW Policy and Procedure!

24
Q

Tamoxifen

A

Gold standard for hormonal treatment of breast cancer
Blocks estrogen receptors on breast cancer cells → decreases rate of tumor growth
Administered orally once daily
Common adverse effects include hot flashes, fluid retention, nausea, vomiting, and menstrual irregularities
Risk for endometrial cancer → acts as an estrogen agonist at receptors in the uterus causing proliferation of endometrial tissue
Can be used as prevention for women at high risk
Not safe for pregnancy

25
Q

Anastrozole

A

Block the enzyme aromatase which is responsible for producing estrogen
Used more often in post-menopausal women (first line therapy)
Does not pose risk of endometrial cancer or thromboembolism
Given orally, once daily
Treatment usually ranges from 2-5 years
Physicians will often start patients on Tamoxifen for 2-3 years and then switch to an aromatase inhibitor for 2-3 years to balance risks and benefits
Side effects include: Increase in MI risk, heart failure, angina, mood swings, and depression

26
Q

Erythropoietin (Epoetin Alpha)

A

Glycoprotein hormone stimulating RBC production in the bone marrow
Not approved for patients with myeloid malignancies and leukemias
Administered intravenously or subcutaneously (degrades in the GI tract, therefore never give PO)
Increased risk of stroke, heart failure, blood clots, MI, and death
May accelerate tumor progression and shorten life in certain patients
Is not recommended for patients except in palliative circumstances

27
Q

Filgrastim (Neupogen)

A

Identical to naturally occurring granulocyte colony stimulating factor (G-CSF)
Elevates neutrophil count in cancer patients
Acts on the bone marrow to increase production of neutrophils
Decreases risk of infection in cancer patients
Should be used cautiously in patients with cancers originating in bone marrow
Given IV or Subcutaneous
Not associated with serious side effects

28
Q

Oprelvekin (Neumega)

A

Nearly identical to Interleukin-11, a cytokine produced in the bone marrow
Stimulates platelet production in the bone marrow
Stimulates proliferation of hematopoietic stem cells and increases synthesis of megakaryocytes that later become platelets
Should not be administered to patients with myeloid cancers
Minimizes thrombocytopenia and reduces the need for platelet transfusions
Administered subcutaneously

29
Q

Alkylating Agents prototype drug

A

Cyclophosphamide

30
Q

Antimetabolites: Folic Acid Analogs prototype drug

A

Methotrexate

31
Q

Antimetabolites: Pyrimidine Analog prototype drug

A

Fluorouracil

32
Q

Antitumor Antibiotics: Doxorubicin prototype drug

A

Doxorubicin (Anthracycline Derivative)

33
Q

Antitumor Antibiotics: Bleomycin prototype drug

A

Bleomycin (Non-Anthracycline Derivative)

34
Q

Mitotic Inhibitors: Vinca Alkaloids prototype drug

A

Vincristine

35
Q

Mitotic Inhibitors: Taxanes prototype drug

A

Paclitaxel

36
Q

Antiestrogens prototype drug

A

Tamoxifen

37
Q

Aromatase Inhibitors prototype drug

A

Anastrozole